Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Astrazeneca Plc ADR
(NQ:
AZN
)
76.90
-0.14 (-0.18%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Astrazeneca Plc ADR
< Previous
1
2
3
4
5
6
7
8
9
...
43
44
Next >
AstraZeneca Settles Heartburn Treatment Lawsuit For One Of Biggest Selling Drug
October 03, 2023
AstraZeneca Plc (NASDAQ: AZN) has
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
Medicare Drug Price Negotiation - What Court's Decision Means for Americans
October 02, 2023
A U.S. District Judge has upheld a pivotal initiative of President Joe Biden, giving the green light for Medicare to commence negotiations on prescription drug prices.
Via
Benzinga
Multi-Billion Dollar Treatment Market For Lung Infection That Causes Over 200,000 Hospitalizations Annually With Elderly, Young At Most Risk Has Game-Changing New Entrant
October 02, 2023
Read the latest report on NanoViricides here
Via
Benzinga
Dianthus' Monoclonal Antibody On Promising Pathway To Gaining The Upper Hand - Analyst
September 28, 2023
Raymond James initiated coverage on Dianthus Therapeutics Inc (NASDAQ: DNTH), a recent reverse merger with the old Magenta Therapeutics.
Via
Benzinga
Pharma Giants Shift Stance, Embrace Medicare Negotiations Amid Rising Drug Costs
September 28, 2023
AstraZeneca Plc (NASDAQ: AZN), Bristol Myers Squibb & Co (NYSE: BMY), and Boehringer Ingelheim are willing to participate in the initial round of Medicare drug price negotiation
Via
Benzinga
AstraZeneca Unusual Options Activity For September 28
September 28, 2023
Via
Benzinga
Ionis-Roche Join Forces To Compete In Neurodegenerative Disease Space, Analyst Sees Short-Term Challenges
September 27, 2023
Ionis Pharmaceuticals Inc (NASDAQ: IONS) entered an agreement with Roche Holdings AG (OTC: RHHBY
Via
Benzinga
Biden's Urgent Action Against Antibiotic-Resistant Bacteria - Allocates $100M to Battle Deadly Superbugs
September 27, 2023
U.S. President Joe Biden is set to unveil a $100 million research initiative to tackle the growing threat of drug-resistant bacteria. More than a million people worldwide succumb to infections caused...
Via
Benzinga
Apple Defends Its $19B Google Search Deal, Hollywood's Writers Secure Credit For AI Training, China's Ambitious Chip Fund Faces Headwinds: Today's Top Stories
September 27, 2023
Benzinga Alibaba's Logistics Arm Cainiao Files For Hong Kong IPO
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Weight Loss Drugs Like Wegovy Could Have Linked Anesthesia Complications, European Medicines Agency To Investigate
September 27, 2023
The European Medicines Agency (EMA) is set to address concerns related to patients taking drugs such as Novo Nordisk A/S's (NYSE
Via
Benzinga
Ionis Climbs On Late-Stage Trial Results For Body Fat Disorder
September 26, 2023
IONS stock rose after Ionis said Olezarsen succeeded in reducing abnormally high levels of body fat inpatients with a rare genetic disorder.
Via
Investor's Business Daily
Multi-Billion Dollar Treatment Market For Lung Infection That Causes Over 200,000 Hospitalizations Annually With Elderly, Young At Most Risk Has Game-Changing New Entrant
September 26, 2023
Read the latest report on NanoViricides here
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 25, 2023
September 25, 2023
Via
Benzinga
Baidu To Rally Over 29%? Here Are 10 Other Analyst Forecasts For Monday
September 25, 2023
Goldman Sachs increased the price target for Constellation Brands, Inc. (NYSE: STZ) from $275 to $305. Goldman Sachs analyst Bonnie Herzog maintained a Buy rating. Constellation shares fell 0.8% to...
Via
Benzinga
3 Magnificent Growth Stocks to Buy Right Now
September 24, 2023
If you're looking for growth, these stocks could be just the ticket.
Via
The Motley Fool
AstraZeneca Surges To 50-Day Line After Breast Cancer Drug Tops Chemo
September 22, 2023
The companies are still testing to see if their drug has a benefit on overall survival.
Via
Investor's Business Daily
Better Than Chemotherapy - AstraZeneca/Daiichi Sankyo Partnered Cancer Drug Meets Primary Goal In Breast Cancer Setting
September 22, 2023
AstraZeneca Plc (NASDAQ: AZN) and Daiichi Sankyo (OTC: DSKYF) (OTC:
Via
Benzinga
Approximately 30% Of Newly Diagnosed Cancers In Women Will Be Breast Cancers – Atossa Therapeutics Has A Promising Drug To Help With Prevention And Treatment
September 15, 2023
One in eight women will be diagnosed with breast cancer during
Via
Benzinga
AstraZeneca's Tagrisso-Chemo Combo Data In Lung Cancer Sets High Bar For Johnson & Johnson's Cancer Drug: Analyst
September 11, 2023
On Sunday night, AstraZeneca Plc (NASDAQ: AZN) presented the Phase 3 FLAURA2 results evaluating Tagrisso plus chemotherapy versus Tagrisso monotherapy as first-line treatment for patients
Via
Benzinga
Qualcomm-Apple's Chip Supply Agreement, Alleged Report About AstraZeneca CEO Sir Pascal Soriot's Intention To Step Down, Apple & Google Face Off in Antitrust Showdown: Today's Top Stories
September 11, 2023
Benzinga Qualcomm Announces Chip Supply Agreement With Apple
Via
Benzinga
What's Going On With AstraZeneca Stock Today?
September 11, 2023
Shares in European pharmaceutical giant AstraZeneca Plc (NASDAQ: AZN) are down amid speculations swirling around the potential departure of AstraZeneca's Chief Executive, Pascal Soriot.
Via
Benzinga
AstraZeneca's Reinforces Hold In Lung Cancer Settings: Touts Promising Data From Three Trials
September 11, 2023
Daiichi Sankyo (OTC: DSKYF) (OTC: DSNKY) and AstraZeneca plc (NASDAQ: AZN) released initial results from the TROPION-Lung04 phase 1b tria
Via
Benzinga
4 Top-Tier Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
September 09, 2023
Deals can still be found with the Nasdaq Composite roughly 14% below its record-closing high.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
Johnson & Johnson Cancer Drug Rybrevant Shows Improvement In Broader Lung Cancer Population
September 06, 2023
Janssen, a unit of Johnson & Johnson (NYSE: JNJ),
Via
Benzinga
FDA Seeks Further Safeguards for AstraZeneca's Ultomiris Therapy, But Efficacy Not in Question
September 06, 2023
The FDA has issued a complete response letter (CRL) regarding AstraZeneca Plc's (NASDAQ:
Via
Benzinga
Exposures
Product Safety
3 Forever Stocks to Buy With $100
September 05, 2023
With $100 or less, you can buy at least one share of one of these top stocks.
Via
The Motley Fool
Facebook News To Shut Down In Europe, Warner Bros. Discovery Revises Outlook As Strike Bites, Manchester United No Longer Up For Sale: Today's Top Stories
September 05, 2023
Benzinga Why Facebook News is Shutting Down in Europe: What It Means for Users?
Via
Benzinga
Legal Twist In Drug Price Negotiation: Federal Judge Quits Case Amid Allegations Of Stock Ownership
September 05, 2023
On Friday, Judge Thomas Rose, serving in the U.S.
Via
Benzinga
8 Pharma Stocks Affected by New Drug Price Negotiation Rules
September 02, 2023
Which companies have the most to lose now that Medicare can negotiate directly with them on the prices of some of the most widely used drugs?
Via
The Motley Fool
Is This Underfollowed Genetic Diagnostics Stock a Buy for Growth Investors?
September 02, 2023
The genetic test maker is rapidly increasing test volumes.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
...
43
44
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.